arrow: clinical activity of pralsetinib in ret-fusion positive solid tumors
Published 3 years ago • 98 plays • Length 6:04Download video MP4
Download video MP3
Similar videos
-
12:19
arrow study: pralsetinib in ret fusion tumors
-
4:05
arrow: precision targeted therapy with pralsetinib for ret fusion tumors
-
2:48
ret fusion-positive mnsclc: selpercatinib and pralsetinib
-
3:18
arrow update confirms pralsetinib benefit for ret fusion-positive advanced nsclc | stephen liu
-
7:34
intracranial activity of selpercatinib in ret fusion positive nsclc
-
7:20
arrow points the way for ret fusion-positive nsclc treatment | stephen liu
-
2:12
the impact of selpercatinib in patients with ret fusion-positive nsclc
-
1:19
phase i/ii trial of ep0031, a next generation selective ret inhibitor
-
4:13
arrow: an update on the registrational study
-
4:00
designing clinical trials for precision oncology
-
2:21
ret fusion treatment: pralsetinib - targeted therapies in lung cancer 2023
-
7:02
fda approval of selpercatinib for ret fusion positive nsclc and thyroid cancers
-
4:58
treatment of nsclc with ret fusions
-
8:43
selpercatinib and pralsetinib in ret disease - lung cancer video library
-
0:51
pralsetinib as a therapeutic option
-
1:30
vivek subbiah, md, describes the incidence of ret-fusion and solid tumors amongst cancer patients
-
4:09
bos172738 in ret-altered tumors
-
3:49
ret fusion treatment: selpercatinib - targeted therapies in lung cancer 2023
-
0:49
dr. strosberg on fda approval of lutathera for gep-nets